=> d bib abs hitstr

L81 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1999:733038 CAPLUS
DN 131:351343
TI Preparation of heterocyclic compounds for the treatment of diabetes and related diseases
IN Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Gurram, Ranga Madhavan; Ramanujam, Rajagopalan; Chakrabarti, Ranjan; Pakala, Sarma K. S.
PA Reddy's Research Foundation, India; Reddy-Cheminor Inc.
SO U.S., 35 pp., Cont.-in-part of U.S. 5,885,997.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5985884	A	19991116	US 1997-884816	19970630
	US 5885997	A	19990323	US 1996-777627	19961231
PRAI	IN 1996-DE1150		19960701		
	US 1996-777627		19961231		

OS MARPAT 131:351343
GI



I



II

AB The title compds. [I; one of X, Y, Z = C(O), C(S) and one of the remaining of X, Y, Z = C and the other C:C; R1-R3 = H, halo, OH, etc.; n = 1-4; Ar =

(un)substituted divalent aryl, heteroaryl; R4 = H, halo, alkyl or forms a bond together with the adjacent group A; A = N, CR5 (wherein R5 = H, halo, alkyl or R5 forms a bond together with R4); B = O, S when A = CR5 and B = O when A = N], novel antidiabetic compds., were prepd. and formulated. Thus, reacting 4-[2-(2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl)ethoxy]benzaldehyde (prepn. given) with thiazolidine-2,4-dione afforded II which showed 67% max. redn. in blood glucose level at 100 mg/kg/day (6 days treatment) in mice.

IT **199114-24-4P 199114-25-5P 199114-26-6P**
199114-27-7P 199114-28-8P 199114-29-9P
199114-30-2P 199114-31-3P 199114-32-4P
199114-33-5P 199114-34-6P 199114-35-7P
199114-36-8P 199114-37-9P 199114-38-0P
199114-39-1P 199114-40-4P 199114-41-5P
199114-42-6P 199114-43-7P 199114-44-8P
199114-45-9P 199114-46-0P 199114-47-1P
199114-48-2P 199114-51-7P 199114-52-8P
199114-54-0P 199114-55-1P 199114-56-2P
199114-57-3P 199114-59-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of heterocyclic compds. for the treatment of diabetes and related diseases)

RN 199114-24-4 CAPLUS
CN Benzaldehyde, 4-[2-(4-methyl-6-oxo-2-propyl-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-25-5 CAPLUS
CN Benzaldehyde, 4-[2-(2,4-dimethyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-26-6 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-27-7 CAPLUS
CN Benzaldehyde, 4-[2-(2-butyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-28-8 CAPLUS
CN Benzaldehyde, 4-[2-[4-methyl-6-oxo-2-(phenylmethyl)-1(6H)-pyrimidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-29-9 CAPLUS
CN Benzaldehyde, 4-[2-(2,5-diethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-30-2 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-6-oxo-4-phenyl-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-31-3 CAPLUS
CN Acetamide, N-[1-[2-(4-formylphenoxy)ethyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 199114-32-4 CAPLUS
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 CAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 CAPLUS
CN Benzaldehyde,
4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]-
(9CI) (CA INDEX NAME)



RN 199114-36-8 CAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-
(9CI) (CA INDEX NAME)



RN 199114-37-9 CAPLUS
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]-
(9CI)
(CA INDEX NAME)



RN 199114-38-0 CAPLUS
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]-
(9CI) (CA INDEX NAME)



RN 199114-39-1 CAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 CAPLUS
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]met

hyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-43-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-ethyl-6-methyl-3-[2-(4-nitrophenoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 199114-44-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-ethyl-3-[2-(4-nitrophenoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 199114-45-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 CAPLUS
CN Benzenepropanoic acid, .alpha.-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 CAPLUS
CN Benzenepropanoic acid, .alpha.-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 CAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-.alpha.-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 CAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-.alpha.-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 CAPLUS
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-55-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-methyl-3-[2-(4-nitrophenoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 199114-56-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 CAPLUS
CN Benzenepropanoic acid, .alpha.-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-59-5 CAPLUS
CN Benzaldehyde, 4-[2-[2-ethyl-6-oxo-4-(trifluoromethyl)-1(6H)-pyrimidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RE.CNT 34
RE
(3) Anon; 1980, 17, CAPLUS
(8) Cantello; Journal of Medicinal Chemistry 1994, V37(23), P3977 CAPLUS
(9) Clark; US 5036079 1991 CAPLUS
(11) Clark, D; J Med Chem 1991, V34, P319 CAPLUS
(14) Dow; US 5498621 1996 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 2

L81 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1999:673737 CAPLUS
DN 132:35672
TI Synthesis and biological activity of some 2-substituted quinazolin-4-ones
AU Spirkova, K.; Stankovsky, S.; Mrvova, A.; Cipak, L'.
CS Department of Organic Chemistry, Faculty of Chemical Technology, Slovak University of Technology, Bratislava, SK-812 37, Slovakia
SO Chem. Pap. (1999), 53(4), 272-275
CODEN: CHPAEG; ISSN: 0366-6352
PB Slovak Academic Press Ltd.
DT Journal
LA English
OS CASREACT 132:35672
GI



I

AB The nonclassical antifolates, e.g. 2-morpholinomethyl-3H-quinazolin-4-one (I), have been prepd. by nucleophilic substitution of bromine in 2-bromomethyl-3H-quinazolin-4-one by nitrogen and oxygen nucleophiles.
IR
and 1H NMR spectra, 13C NMR data of selected compds., basic antibacterial and cytotoxic activities are presented.
IT **120244-31-7P 252570-63-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and biol. activity of quinazolinones as antibacterial and antitumor agents)
RN 120244-31-7 CAPLUS
CN 4(1H)-Quinazolinone, 2-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 252570-63-1 CAPLUS
CN 4(1H)-Quinazolinone, 2-[(2-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 10
RE
(1) Gupta, C; J Med Chem 1968, V11, P392 CAPLUS
(2) Horakova, K; Neoplasma 1988, V35, P169 CAPLUS
(3) Hudecova, D; Folia Microbiol 1996, V41, P473 CAPLUS
(4) Jantova, S; Cell Biochem Funct 1993, V11, P131 CAPLUS
(5) Jantova, S; Folia Microbiol 1997, V42, P324 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 3

L81 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1999:212642 CAPLUS
DN 130:223293
TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
IN Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema
PA Reddy's Research Foundation, India; Reddy-Cheminor, Inc.
SO U.S., 26 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5885997	A	19990323	US 1996-777627	19961231
	CA 2258949	AA	19971106	CA 1997-2258949	19970630
	WO 9741097	A2	19971106	WO 1997-US11522	19970630
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9737198	A1	19971119	AU 1997-37198	19970630
	US 5985884	A	19991116	US 1997-884816	19970630
	NO 9806055	A	19981222	NO 1998-6055	19981222
PRAI	IN 1996-DE1150	19960701			
	US 1996-777627	19961231			
	WO 1997-US11522	19970630			

OS MARPAT 130:223293
GI



I



II

AB The present invention relates to novel antidiabetic compds., their tautomeric forms, their derivs., their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compns. contg. them. This invention particularly relates to novel azolidinedione derivs., and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compns. contg. them. Approx. 30 title compds. such as I (R = Pr, Me, Et, Bu, benzyl) and their quinazoline analogs were prepd. in 66-99% yields, e.g., by condensation of aldehydes II with thiazolidine-2,4-dione. Antidiabetic data was given for several of the prepd. compds. At 30 mg/kg/day, after 6 days, 5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,5-dihydro-1-pyrimidinyl]ethoxy]phenylmethyl] thiazolidine-2,4-dione reduced the blood glucose level 73%, lowered triglycerides 70% and also lowered cholesterol in the rat.

IT **199114-24-4P 199114-25-5P 199114-26-6P**
199114-27-7P 199114-28-8P 199114-29-9P
199114-30-2P 199114-31-3P 199114-32-4P
199114-33-5P 199114-34-6P 199114-35-7P
199114-36-8P 199114-37-9P 199114-38-0P
199114-39-1P 199114-40-4P 199114-41-5P
199114-42-6P 199114-43-7P 199114-44-8P
199114-45-9P 199114-46-0P 199114-47-1P
199114-48-2P 199114-51-7P 199114-52-8P
199114-54-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyrimidinylethoxybenzylthiazolidinediones)

RN 199114-24-4 CAPLUS

CN Benzaldehyde, 4-[2-(4-methyl-6-oxo-2-propyl-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-25-5 CAPLUS
CN Benzaldehyde, 4-[2-(2,4-dimethyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-26-6 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-27-7 CAPLUS
CN Benzaldehyde, 4-[2-(2-butyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-28-8 CAPLUS
CN Benzaldehyde, 4-[2-[4-methyl-6-oxo-2-(phenylmethyl)-1(6H)-pyrimidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-29-9 CAPLUS
CN Benzaldehyde, 4-[2-(2,5-diethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-30-2 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-6-oxo-4-phenyl-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-31-3 CAPLUS
CN Acetamide, N-[1-[2-(4-formylphenoxy)ethyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 199114-32-4 CAPLUS
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 CAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 CAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 CAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 CAPLUS
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]-(9CI)
(CA INDEX NAME)



RN 199114-38-0 CAPLUS
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]-(9CI) (CA INDEX NAME)



RN 199114-39-1 CAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 CAPLUS
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-43-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-ethyl-6-methyl-3-[2-(4-nitrophenoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 199114-44-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-ethyl-3-[2-(4-nitrophenoxy)ethyl]- (9CI) (CA INDEX

NAME)



RN 199114-45-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX
NAME)



RN 199114-47-1 CAPLUS
CN Benzenepropanoic acid,*.alpha.-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 CAPLUS
CN Benzenepropanoic acid, .alpha.-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 CAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-.alpha.-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 CAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-.alpha.-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 CAPLUS
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RE.CNT 57
RE
(1) Anon; EP 008203 A 1980 CAPLUS
(6) Anon; EP 0207581 1987 CAPLUS
(8) Anon; EP 0306228 1989 CAPLUS
(9) Anon; EP 0332331 1989 CAPLUS
(10) Anon; EP 0332332 1989 CAPLUS

Searched by John Dantzma 703-308-4488

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 4

L81 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1999:152363 CAPLUS
DN 130:196665
TI Preparation of .omega.-[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPAR.alpha. and PPAR.gamma. receptor agonists
IN Lohray, Vidya Hushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Ramanujam, Rajagopalan; Chakrabarti, Ranjan
PA Reddy's Research Foundation, India; Reddy-Cheminor, Inc.
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9908501	A2	19990225	WO 1998-US22568	19981026
WO 9908501	A3	19990415		

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-82825 19980423
OS MARPAT 130:196665
GI



I

AB Title compds. [I; R = (CH2)nOZCHR4CR5(OR6)COYR7 and R3 = H, halo, alkyl, alkoxy, etc.; R = H, OH, acyl, alkyl, etc.; and R3 = (CH2)nOZCHR4CR5(OR6)COYR7; R1,R2 = H, halo, alkyl, alkoxy, etc.; R1R2 = atoms to complete a ring; R4,R5 = H, halo, alkyl, alkoxy, etc.;; R4R5 = bond; R6 = H, acyl, alkyl aryl, etc.; R7 = H, alkyl, heterocyclyl, (hetero)aryl, etc.; X = O or S; Y = O or NR8; R8 = H, alkyl, aryl, etc.; R7R8 = atoms to complete a ring; Z = (hetero)arylene; n = 1-4] were prepd.
Thus, I (R = Me, R1R2 = CH:CHCH:CH, X = O)(II; R3 = CH2Cl) was condensed with 4-(HO)C6H4CH2CH(OEt)CO2Et to give II [R3 = CH2OC6H4[CH2CH(OEt)CO2Et]-4]. Data for biol. activity of I were given.
IT **220746-26-9P 220746-27-0P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .omega.-[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPAR.alpha. and PPAR.gamma. receptor agonists)

RN 220746-26-9 CAPLUS
CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-.alpha.-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-27-0 CAPLUS
CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-.alpha.-hydroxy- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 5

L81 ANSWER 5 OF 40 CAPLUS, COPYRIGHT 2000 ACS
AN 1999:64689 CAPLUS
DN 130:139576
TI Preparation of cyclin dependent kinase inhibiting purine derivatives
IN Griffin, Roger John; Calvert, Alan Hilary; Curtin, Nicola Jane; Newell, David Richard; Golding, Bernhard Thomas; Endicott, Jane Anne; Noble, Martin Edward Mantyla; Boyle, Francis Thomas; Jewsbury, Philip John
PA Newcastle University Ventures Limited, UK
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9902162	A1	19990121	WO 1998-GB2025	19980710
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9882342	A1	19990208	AU 1998-82342	19980710
PRAI	GB 1997-14603		19970712		
	GB 1998-6743		19980828		
	WO 1998-GB2025		19980710		

OS MARPAT 130:139576
GI



I



II

AB Purine derivs. I [X = O, S or CHRx; Rx = H, C1-4-alkyl; D = H, halo, NZ1Z2; Z1, Z2 = H, C1-4-alkyl, C1-4-hydroxyalkyl; A = H, C1-4-alkyl, C1-4-alkoxy, OH, CH2(CH2)nOH, NRa1Ra2; n = 1 - 4; Ra1, Ra2 = H, C1-4-alkyl; B = H, C1-4-alkyl, C1-4-alkoxy, CF3, (un)substituted aryl, (e.g. Ph), (un)substituted aralkyl (e.g. benzyl), hydroxy group that provides a C=O tautomer; Y = (un)substituted C4-8-carbocyclic, -heterocyclic ring, (un)substituted linear or branched hydrocarbon chain] which can act as inhibitors of cyclin dependent kinases (CDKs) and which thereby can provide useful therapeutic compds. for use in treatment of

tumors or other cell proliferation disorders are disclosed. The compds. of this invention bind to CDK mols. in a manner that appears to be different to that of known CDK inhibitors such as olomoucine and roscovitine. Thus, O6-[(cyclohex-3-en-1-yl)methyl]guanine (II) was prepd.
from 2-amino-6-chloropurine via addn. to 3-cyclohexenemethanol in THF contg. sodium hydride. II is an active inhibitor of cyclin dependent kinases: IC50 = 3.2 .mu.M vs. CDK1, 87% inhibition of CDK2 at 100.mu.M and
53% inhibition of CDK4.

IT **219991-62-5P**, 2-Amino-6-[(uracil-5-yl)methoxy]-8-oxopurine
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of purine derivs. as cyclin dependent kinase inhibitors)

RN 219991-62-5 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-[[(2-amino-7,8-dihydro-8-oxo-1H-purin-6-yl)oxy]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 15

RE

(1) Arris, C; Anti-Cancer Drug Design 1994, V9(5), P401 CAPLUS
(5) Chae, M; Journal of Medicinal Chemistry 1994, V37(3), P342 CAPLUS
(6) Chae, M; Journal of Medicinal Chemistry 1995, V38(2), P359 CAPLUS
(8) Havlicek, L; Journal of Medicinal Chemistry 1997, V40(4), P408 CAPLUS
(10) Krenitsky, T; Journal of Medicinal Chemistry 1989, V32(7), P1471 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 6

L81 ANSWER 6 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1998:485432 CAPLUS
DN 129:175649
TI Quinazolines useful as nitric oxide synthase (NOS) inhibitors
IN Gaku, Kazuhiko; Nishino, Shigetaka; Fuji, Tetsuo; Kato, Takeshi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10195058	A2	19980728	JP 1997-352820	19971222
PRAI AU 1996-4404		19961230		

OS MARPAT 129:175649
GI



I

AB Quinazolines I [R1 = H, halo, substituted lower alkylamino; R2, R3 = H, halo; R4 = H, amino, acylamino, di(lower)alkylamino, amidino, thiazolinylamino, [(imino)(thienyl)methyl]amino, piperidino, 1-imidazolyl, cyano, OH, acyloxy, protected carboxy, dioxolanyl, oxotetrahydropyranyl, (imino)(lower alkoxy)methyl; A1 = lower alkylene; A2 = bond, O, NH, CHOH, CO; A3 = bond, phenylene, pyridonediyl, (lower alkoxy-substituted) pyridinediyl; A4 = bond, lower alkylene; when A2 is CO, then A4 is lower alkylene; when both A2 and A3 are bonds, then R4 is not H nor protected carboxy] or their salts, useful as NOS inhibitors for treatment of various diseases, are claimed. Biol. activity data are not given. Cyclization of 0.15 g N-[2-[2-[(2-carbamoyl-3,5-dichlorophenyl)amino]ethoxy]benzyl]acetamide (prepn. given) with 0.18 g 1,1'-carbonyldiimidazole gave 0.13 g N-[2-[2-(5,7-dichloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl)ethoxy]benzyl]acetamide.

IT **211378-78-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinazolines as nitric oxide synthase inhibitors)

RN 211378-78-8 CAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 1-[2-(2-aminophenoxy)ethyl]-5,7-dichloro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> d bib abs hitstr 7

L81 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1997:740205 CAPLUS
DN 128:13282
TI Preparation of thiazolidinediones and analogs as antidiabetics
IN Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Gurram, Ranga Madhavan; Ramanujam, Rajagopalan; Chakrabarti, Ranjan; Pakala, Sarma K. S.
PA Dr. Reddy's Research Foundation, India; Reddy-Cheminor, Inc.
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9741097	A2	19971106	WO 1997-US11522	19970630
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5885997	A	19990323	US 1996-777627	19961231
	AU 9737198	A1	19971119	AU 1997-37198	19970630
	EP 958296	A1	19991124	EP 1997-934041	19970630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	NO 9806055	A	19981222	NO 1998-6055	19981222
PRAI	US 1996-777627	19961231			
	IN 1996-DE1150	19960701			
	WO 1997-US11522	19970630			

OS MARPAT 128:13282
GI



I II

AB Title compds. [I; A = N, CR5; B = O or S; R = CHR4ZO(CH2)nR1; R1 = (un)substituted pyrimidinyl, -quinazolinyl, etc.; R4,R5 = H, halo, alkyl; R4R5 = bond; Z = divalent arom. or heterocyclic group; n = 1-4] were prepd. Thus, 4-methyl-2-propyl-1,6-dihydro-6-pyrimidinone was N-alkylated by 4-(BrCH2CH2O)C6H4CHO and the product condensed with

thiazolidine-2,4-dione to give, after hydrogenation, title compd. II. Data for biol. activity of I were given.

IT **199114-24-4P 199114-25-5P 199114-26-6P**
199114-27-7P 199114-28-8P 199114-29-9P
199114-30-2P 199114-31-3P 199114-32-4P
199114-33-5P 199114-34-6P 199114-35-7P
199114-36-8P 199114-37-9P 199114-38-0P
199114-39-1P 199114-40-4P 199114-41-5P
199114-42-6P 199114-43-7P 199114-44-8P
199114-45-9P 199114-46-0P 199114-47-1P
199114-48-2P 199114-51-7P 199114-52-8P
199114-54-0P 199114-55-1P 199114-56-2P
199114-57-3P 199114-59-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of thiazolidinediones and analogs as antidiabetics)

RN 199114-24-4 CAPLUS
CN Benzaldehyde, 4-[2-(4-methyl-6-oxo-2-propyl-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-25-5 CAPLUS
CN Benzaldehyde, 4-[2-(2,4-dimethyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-26-6 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-27-7 CAPLUS
CN Benzaldehyde, 4-[2-(2-butyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-28-8 CAPLUS
CN Benzaldehyde, 4-[2-[4-methyl-6-oxo-2-(phenylmethyl)-1(6H)-pyrimidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-29-9 CAPLUS
CN Benzaldehyde, 4-[2-(2,5-diethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-30-2 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-6-oxo-4-phenyl-1(6H)-pyrimidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-31-3 CAPLUS
CN Acetamide, N-[1-[2-(4-formylphenoxy)ethyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 199114-32-4 CAPLUS
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 CAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 CAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 CAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-
(9CI) (CA INDEX NAME)



RN 199114-37-9 CAPLUS
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]-
(9CI)
(CA INDEX NAME)



RN 199114-38-0 CAPLUS
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]-
(9CI) (CA INDEX NAME)



RN 199114-39-1 CAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-

methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 CAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 CAPLUS
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-43-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-ethyl-6-methyl-3-[2-(4-nitrophenoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 199114-44-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-ethyl-3-[2-(4-nitrophenoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 199114-45-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 CAPLUS
CN Benzenepropanoic acid, .alpha.-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 CAPLUS
CN Benzenepropanoic acid, .alpha.-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 CAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-.alpha.-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 CAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-.alpha.-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 CAPLUS
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-55-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-methyl-3-[2-(4-nitrophenoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 199114-56-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 CAPLUS
CN Benzenepropanoic acid, .alpha.-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-59-5 CAPLUS
CN Benzaldehyde, 4-[2-[2-ethyl-6-oxo-4-(trifluoromethyl)-1(6H)-pyrimidinyl]ethoxy]- (9CI) (CA INDEX NAME)


Et
N
N
CH2
CH2
O
F3C
O
CHO

=> d bib abs hitstr 8

L81 ANSWER 8 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1997:553183 CAPLUS
DN 127:205585
TI Preparation of benzoazines for reducing blood glucose level
IN Nagao, Yoshihiro; Ito, Yoshikuni; Kotake, Jiro; Kouda, Tadayuki; Honda, Haruyoshi; Sato, Susumu; Matsuda, Hideaki
PA SS Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 787727	A1	19970806	EP 1997-101626	19970131
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	JP 09268189	A2	19971014	JP 1997-15135	19970129
	CA 2196400	AA	19970801	CA 1997-2196400	19970130
	US 5710152	A	19980120	US 1997-791269	19970130
	CN 1167764	A	19971217	CN 1997-101300	19970131
PRAI	JP 1996-14898		19960131		

OS MARPAT 127:205585
GI



I



II

AB The title compds. [I; R1 = alkyl, alkoxy, halo, etc.; R2, R3 = H, alkyl; R2R3 = C2-7 alkylene; R4, R5 = H, alkyl; X = O, S, NR6 (wherein R6 = H, alkyl, aryl, pyridyl); m = 0-4; n = 1-3] which exhibit superior effects for reducing blood glucose value, plasma insulin value, and plasma triglyceride value, and are useful as a medicament for preventing or treating diabetes, hyperlipidemia, and obesity, were prepd. Thus, reaction of 4-[2-(4-oxo-3,4-dihydro-2H-1,3-benzoxazin-3-yl)ethoxy]benzaldehyde with 2,4-thiazolidinedione in the presence of a

catalytic amt. of AcOH and piperidine in PhMe followed by hydrogenation of the resulting thiazolidinedione II over 10% Pd/C in 1,4-dioxane afforded I [R1-R5 = H; X = O; n = 1] which showed 65.8% blood glucose redn. at 9.8 mg/kg/day.

IT **194713-69-4P 194713-70-7P 194713-71-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of benzoazines for reducing blood glucose level)

RN 194713-69-4 CAPLUS
CN Benzaldehyde, 4-[2-(1,4-dihydro-4-oxo-1-phenyl-3(2H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 194713-70-7 CAPLUS
CN Benzaldehyde, 4-[2-(1,4-dihydro-1-methyl-4-oxo-3(2H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 194713-71-8 CAPLUS
CN Benzaldehyde, 4-[2-[1,4-dihydro-4-oxo-1-(2-pyridinyl)-3(2H)-quinazolinyl]ethoxy]- (9CI) (CA INDEX NAME)


N
N
N
CH2
CH2
O
CHO
O

=> d bib abs hitstr 9

L81 ANSWER 9 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1995:887878 CAPLUS
DN 123:286023
TI Preparation of 5-[4-(heterocyclylalkoxy)benzyl - or benzylidene]thiazolidine-2,4-dione derivatives as hypolipidemics and hypoglycemics
IN Yano, Shingo; Ogawa, Kazuo; Fukushima, Masakazu
PA Taiho Pharmaceutical Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 57 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07138258	A2	19950530	JP 1993-286509	19931116
	CA 2177553	AA	19971129	CA 1996-2177553	19960528
PRAI	JP 1993-286509	19931116			

OS MARPAT 123:286023
GI For diagram(s), see printed CA Issue.
AB The title compds. [I; R1, R2 = H, halo, lower (halo)alkyl or (halo)alkoxy; or R1 and R2 are bonded together to form C1-3 alkylenedioxy; X = N, CH; the single bond with a dotted line represents a single bond or a double bond; A = heterocyclyl selected from Q - Q5; R3, R4 = H, lower alkyl; n = 1-4], having little side effects and useful as antidiabetics having activity for lowering both sugar and lipids in blood, are prepd. Thus, a soln. of benzaldehyde deriv. Q6-CHO (R1 = CF3) (prepn. given) 9.5, 2,4-thiazolidinone 3.8, and AcONa 4.3 g in 50 mL toluene was refluxed for 15 h and the solvent was removed by distn. to give, after treatment with 80% aq. AcOH and filtration of pptd. crystals, 76% 5-benzylidene-2,4-thiazolidinone deriv. (II; R = Q6, wherein R1 = CF3) which was hydrogenated over 5% Pd-C in 1,4-dioxane at 50.degree. and H pressure 50 atm to give 80% 5-benzyl-2,4-thiazolidinone deriv. (III; R = Q6, wherein R1 = CF3) (IV). IV and III (R = Q6, wherein R1 = CF3O) at 2.5 mg/kg p.o. twice a day for 5 consecutive days lowered the blood sugar level by 41 and 53%, resp., in mice.
IT **169548-02-1P 169548-03-2P 169548-04-3P 169548-05-4P 169548-06-5P 169548-07-6P 169548-08-7P 169548-09-8P 169548-10-1P 169548-11-2P 169548-12-3P 169548-13-4P 169548-14-5P 169548-15-6P 169548-16-7P 169548-17-8P 169548-18-9P 169548-19-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (intermediate for prepn. of [(heterocyclylalkoxy)benzyl - or benzylidene]thiazolidinedione derivs. as hypolipidemics and hypoglycemics)
RN 169548-02-1 CAPLUS
CN Benzaldehyde, 4-[2-[2-oxo-3-[4-(trifluoromethoxy)phenyl]-1-imidazolidinyl]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 169548-03-2 CAPLUS
CN Benzaldehyde, 4-[2-[2-oxo-3-[4-(trifluoromethyl)phenyl]-1-imidazolidinyl]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 169548-04-3 CAPLUS
CN Benzaldehyde, 4-[2-[3-(4-chlorophenyl)-2-oxo-1-imidazolidinyl]ethoxy]-
(9CI) (CA INDEX NAME)



RN 169548-05-4 CAPLUS
CN Benzaldehyde,
4-[2-[3-(3,4-difluorophenyl)-2-oxo-1-imidazolidinyl]ethoxy]-
(9CI) (CA INDEX NAME)



RN 169548-06-5 CAPLUS
CN Benzaldehyde,
4-[2-[3-(2,4-dichlorophenyl)-2-oxo-1-imidazolidinyl]ethoxy]-
(9CI) (CA INDEX NAME)



RN 169548-07-6 CAPLUS
CN Benzaldehyde, 4-[2-[3-(1,3-benzodioxol-5-yl)-2-oxo-1-
imidazolidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 169548-08-7 CAPLUS
CN Benzaldehyde, 4-[2-(2-oxo-3-phenyl-1-imidazolidinyl)ethoxy]- (9CI) (CA
INDEX NAME)



RN 169548-09-8 CAPLUS
CN Benzaldehyde, 4-[2-[3-(4-chloro-2-fluorophenyl)-2-oxo-1-imidazolidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 169548-10-1 CAPLUS
CN Benzaldehyde, 4-[2-[3-(4-methoxyphenyl)-2-oxo-1-imidazolidinyl]ethoxy]- (9CI) (CA INDEX NAME)



OMe

RN 169548-11-2 CAPLUS
CN Benzaldehyde, 4-[2-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]ethoxy]-
(9CI) (CA INDEX NAME)



F

RN 169548-12-3 CAPLUS
CN Benzaldehyde, 4-[2-[3-(3-fluorophenyl)-2-oxo-1-imidazolidinyl]ethoxy]-

(9CI) (CA INDEX NAME)



RN 169548-13-4 CAPLUS
CN Benzaldehyde, 4-[2-[3-(2-methoxyphenyl)-2-oxo-1-imidazolidinyl]ethoxy]-
(9CI) (CA INDEX NAME)



RN 169548-14-5 CAPLUS
CN Benzaldehyde, 4-[2-[2-oxo-3-(3-pyridinyl)-1-imidazolidinyl]ethoxy]- (9CI)
(CA INDEX NAME)



RN 169548-15-6 CAPLUS
CN Benzaldehyde, 4-[2-[3-(6-methoxy-3-pyridinyl)-2-oxo-1-imidazolidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 169548-16-7 CAPLUS
CN Benzaldehyde, 4-[3-[3-(4-chlorophenyl)-2-oxo-1-imidazolidinyl]propoxy]-

(9CI) (CA INDEX NAME)



RN 169548-17-8 CAPLUS
CN Benzaldehyde, 4-[3-[2-oxo-3-[4-(trifluoromethyl)phenyl]-1-imidazolidinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 169548-18-9 CAPLUS
CN Benzaldehyde, 4-[3-[3-(3,4-difluorophenyl)-2-oxo-1-imidazolidinyl]propoxy]-

(9CI) (CA INDEX NAME)



RN 169548-19-0 CAPLUS
CN Benzaldehyde, 4-[3-[3-(4-chloro-2-fluorophenyl)-2-oxo-1-imidazolidinyl]propoxy]- (9CI) (CA INDEX NAME)



IT **169548-93-0**
RL: RCT (Reactant)
(reaction in prepn. of [(heterocyclylalkoxy)benzyl - or

benzylidene]thiazolidinedione derivs. as hypolipidemics and hypoglycemics)

RN 169548-93-0 CAPLUS

CN Benzaldehyde, 4-[[1-(4-ethylphenyl)-5-methyl-2-oxo-4-imidazolidinyl]methoxy]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 10

L81 ANSWER 10 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1995:572524 CAPLUS
DN 123:228160
TI Synthesis, activity and toxicity of novel macrocyclic ligands against HIV-1 in Jurkat and CEM-SS cell lines
AU Balogh-Nair, V.; Brathwaite, C. E.; Chen, C. X.; Vargas, J., Jr.
CS Dep. Chem., The City College of New York, New York, NY, 10031, USA
SO Cell. Mol. Biol. (Paris) (1995), 41(Suppl. 1), S9-S14
CODEN: CMOBEF; ISSN: 0145-5680
DT Journal
LA English
AB A synthetic routes that affords metal-free macrocycles contg. different functionalities in their framework was developed. Novel oxaziridine-contg. and amide-contg. macrocycles were synthesized, and the metal complexes of the latter were also prepd. A series of theophylline and thymidine side-arm contg. podands as well as macrocycles were obtained employing the same methodol. The primary anti-viral tests of these synthetic compds. for anti-HIV activity was carried out using the XTT-based cytotoxicity assay (CEM-SS cells) with AZT as pos. control. It was found that the nature of the macrocyclic headgroups affected the anti-HIV-1 activity. Heteroatom contg. macrocyclic headgroups displayed activity in the micromolar range. Metal complexation did not enhance the activity and side-arm substitution resulted in inactive compds. Cell viability detd. in both Jurkat and CEM-SS cells was strongly dependent on the structure of the macrocyclic framework. The oxaziridine moieties in the macrocycle were highly toxic to CEM-SS and less toxic to Jurkat cell lines, while amide contg. macrocycles were toxic to neither.
IT **168650-19-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and virucidal activity and toxicity of macrocyclic ligands)
RN 168650-19-9 CAPLUS
CN 1H-Purine-2,6-dione, 7,7'-[methylenebis[(4-nitro-2,1-phenylene)oxy-2,1-ethanediyl]]bis[3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 11

L81 ANSWER 11 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1995:560596 CAPLUS
DN 122:309889
TI Potential bioreductively activated hypoxia probes and post-irradiation radiosensitizers related to NITP
AU Mehta, Lina K.; Monney, Hugh; Parrick, John; Hodgkiss, Richard J.
CS Chem. Dep., Brunel Univ., Middlesex, UB8 3PH, UK
SO Anti-Cancer Drug Des. (1995), 10(3), 227-41
CODEN: ACDDEA; ISSN: 0266-9536
DT Journal
LA English
AB NITP (1) is an effective marker of hypoxia in tumors for both microscopy and cell sorting studies and, addnl., the compd. shows postirradn. sensitization, probably by inhibition of repair of radiation damage to DNA. However, NITP does not have the substitution pattern which the immunochem. reagents are raised to recognize and the compd. has very low soly. in water. We report the synthesis of an isomer (13) of NITP which has the desirable substitution pattern and is also sol. in very weak aq. base. The successful synthesis of 13 uses a nitrosation and cyclization of a substituted uracil (16), but earlier approaches from 5 and 12 yielded the pyridoxanthine deriv. 6. The preparative use of nitro group displacement reactions from 8-nitrocaffeine is shown to be a useful entry to a range of 8-substituted caffeines and is utilized to obtain two derivs. of NITP which carry aliph. amine chains, i.e., 34 and 35.
IT **152538-24-4**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(potential bioreductively activated hypoxia probes and radiosensitizers related to NITP)
RN 152538-24-4 CAPLUS
CN 1H-Purine-2,6-dione, 7-[4-[(3-amino-1,4-dioxido-1,2,4-benzotriazin-7-yl)oxy]butyl]-3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> d bib abs hitstr 12

L81 ANSWER 12 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1995:203474 CAPLUS
DN 122:81305
TI Preparation of ethers and esters of 2,3-bis(hydroxymethyl)quinoxaline 1,4-dioxide under phase-transfer catalysis conditions
AU Fridman, I. A.; Nikonova, I. V.; Koldobskii, G. I.
CS St. Peterburg. Gos. Tekhnol. Inst., Russia
SO Khim. Geterotsikl. Soedin. (1994), (6), 816-20
CODEN: KGSSAQ; ISSN: 0132-6244
DT Journal
LA Russian
AB The title compds. were prepd. by reaction of 2,3-bis(bromomethyl)quinoxaline 1,4-dioxide with phenols and carboxylic acids in phase-transfer systems. The catalytic activities of tetrabutylammonium bromide and cetyltriethylammonium bromide were compared.
IT **160252-97-1P 160252-99-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 160252-97-1 CAPLUS
CN Benzaldehyde, 4,4'-[(1,4-dioxido-2,3-quinoxalinediyl)bis(methyleneoxy)]bis- (9CI) (CA INDEX NAME)



RN 160252-99-3 CAPLUS
CN Quinoxaline, 2,3-bis[(4-nitrophenoxy)methyl]-, 1,4-dioxide (9CI) (CA INDEX NAME)



=> d bib abs hitstr 13

L81 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1994:681046 CAPLUS
DN 121:281046
TI Neutral ditopic receptors for adenosine monophosphate
AU Lacy, Stephen M.; Rudkevich, Dmitry M.; Verboom, Willem; Reinhoudt, David N.
CS Lab. Org. Chem., Univ. Twente, Enschede, 7500 AE, Neth.
SO Tetrahedron Lett. (1994), 35(32), 5953-6
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
AB Novel neutral ditopic receptors for AMP2- consisting of an immobilized Lewis acidic uranyl center covalently coupled to thymine are described.
IT **158793-00-1P 158793-01-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of neutral ditopic uranyl thymines as receptors for adenosine monophosphate)
RN 158793-00-1 CAPLUS
CN Benzaldehyde, 3-[4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)butoxy]-2-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 158793-01-2 CAPLUS
CN Benzaldehyde, 3-[4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)butoxy]-2-hydroxy- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 14

L81 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1994:164092 CAPLUS
DN 120:164092
TI Pyrimidinones as reversible metaphase arresting agents
AU Benneche, T.; Strande, P.; Oftebro, R.; Undheim, K.
CS Dep. Chem., Univ. Oslo, Oslo, N-0315, Norway
SO Eur. J. Med. Chem. (1993), 28(6), 463-72
CODEN: EJMCA5; ISSN: 0223-5234
DT Journal
LA English
GI



I

AB 5-Halo-N(1)-substituted 2(1H)-pyrimidinones, e.g. I (X = O, S, NCO2Et; n =
0, 1; R = H, 2-Me, 4-Cl) were prepd. as agents to cause reversible arrest of mitosis during metaphase. In vitro data have been provided. It is suggested that reversible metaphase inhibitors can be used as synchronizing agents of cell-cycles by applying them in a sequential manner when a phase-specific cytotoxic drug is used in the treatment of diseases caused by uncontrolled rapidly proliferating cells. The active compds. are prepd. from 2-pyrimidinones by alkylation reactions. The key reactants are .alpha.-chloroalkyl ethers, sulfides and amides; methods for
their syntheses have been described.

IT **100944-95-4P 100945-07-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as reversible metaphase arresting agent)

RN 100944-95-4 CAPLUS
CN Benzaldehyde, 4-[(5-chloro-2-oxo-1(2H)-pyrimidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 100945-07-1 CAPLUS
CN Benzaldehyde, 4-[[2-oxo-5-(trifluoromethyl)-1(2H)-pyrimidinyl]methoxy]-

LA English
GI



I

AB The i.p. LD50 values of the 14 quinazolones I (R = Cl, MeO, or NO2; R1 = H
or Br; R2 = H, Br, I; R3 = pyridyl or thiazolyl) tested in mice were .gtoreq.700 mg/kg. Almost all the compds. depressed the behavioral parameters measured. 2-(o-Methoxyphenoxymethyl)-3-(2'-thiazolyl)-4-quinazolone [73342-49-1] gave the best protection against pentylenetetrazol-induced seizures, decreasing the death rate by 60% when injected i.p. at 100 mg/kg 4 h before administration of the convulsant. Structure anticonvulsant activity relations are discussed.

IT **73342-54-8 73342-55-9**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)

RN 73342-54-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-nitrophenoxy)methyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 73342-55-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-nitrophenoxy)methyl]-3-(2-thiazolyl)- (9CI) (CA INDEX NAME)



L81 ANSWER 30 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1976:164678 CAPLUS
DN 84:164678
TI Benzazoles. XXX. Amidomethylation of aromatic compounds with 1,3-bischloromethylbenzimidazolone and 1,3-bischloromethylbenzimidazolethi one
AU Zinner, H.; Nitzsche, W.
CS Sekt. Chem., Univ. Rostock, Rostock, E. Ger.
SO J. Prakt. Chem. (1976), 318(1), 144-8
CODEN: JPCEAO
DT Journal
LA German
GI



AB (Chloromethyl)benzimidazoles I (X = O, S; R = Cl) (II) when treated with R1H (R1 = Ph, 4-MeC6H4, 2,5-Me2C6H3) in presence of AlCl3 yielded 52-82% I (R = R1). The reaction of II and phenoxides NaOR2 (R2 = Ph, 4-ClC6H4, C6Cl5) and KOC6H4NO2-4 gave 55-90% I (X = O, S; R = R2, OC6H4NO2-4).
IT **59103-49-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 59103-49-0 CAPLUS
CN 2H-Benzimidazole-2-thione, 1,3-dihydro-1,3-bis[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



L81 ANSWER 31 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1976:38578 CAPLUS
DN 84:38578
TI Correlation analysis of Baker's studies on enzyme inhibition. 2. Chymotrypsin, trypsin, thymidine phosphorylase, uridine phosphorylase, thymidilate synthetase, cytosine nucleoside deaminase, dihydrofolate reductase, malate, glutamate, lactate, and glyceraldehyde-phosphate dehydrogenase
AU Yoshimoto, Masafumi; Hansch, Corwin
CS Dep. Chem., Pomona Coll., Claremont, Calif., USA
SO J. Med. Chem. (1976), 19(1), 71-98
CODEN: JMCMAR
DT Journal
LA English
AB The inhibitory activity of .apprx.1000 inhibitors of the title enzymes, .alpha.-chymotrypsin [9004-07-3], trypsin [9002-07-7], thymidine phosphorylase [9030-23-3], uridine phosphorylase [9030-22-2], thymidylate synthetase [9031-61-2], cytosine nucleoside deaminase [9025-06-3], dihydrofolate reductase [9002-03-3], malate dehydrogenase [9001-64-3], glutamate dehydrogenase [9001-46-1], glyceraldehyde-phosphate dehydrogenase [9001-50-7], and lactate dehydrogenase [9001-60-9], were formulated in 13 equations correlating chem. structure with inhibiting potency. Two types of regions in enzymes were defined by means of .pi. and molar refractive consts. The correlation equations showed that substituent effects are additive to a 1st approxn. Examples are given of use of the equations in comparing structural features of different systems.
IT **23572-67-0 26147-08-0 26147-09-1**
26147-10-4 26159-11-5 57278-35-0
RL: BIOL (Biological study)
(cytosine nucleoside deaminase inhibition by, correlation anal. in relation to)
RN 23572-67-0 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-(3,4-dichlorophenyl)-1-[3-(2-nitrophenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 26147-08-0 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-(2-nitrophenoxy)propyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 26147-09-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-(3-nitrophenoxy)propyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 26147-10-4 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-(4-nitrophenoxy)propyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 26159-11-5 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-(3-chloro-4-nitrophenoxy)propyl]-5-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 57278-35-0 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-(2,4-dichloro-6-nitrophenoxy)propyl]-5-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



L81 ANSWER 32 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1974:463633 CAPLUS
DN 81:63633
TI 5-Methyl-5-phenoxymethylhydantoins
IN Blaha, Ludvik; Weichet, Jaroslav
SO Czech., 4 pp.
CODEN: CZXXA9
DT Patent
LA Czech
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CS 151744	B	19731119	CS 1971-357	19710119

GI For diagram(s), see printed CA Issue.
AB The title compds. I (R = OCH2Ph, OH, Me, OMe, Cl, NO2, NH2) were prepd. in 81-96% yield by reaction of RnC6H5-nOCH2COMe with (NH4)2CO3 and KCN in an aq.-alc. soln. 4 hr at room temp. and 15 hr at 45-50.degree.. The aminophenoxy and hydroxyphenoxy derivs. were prepd., resp., by hydrogenation and debenzylation of the corresponding nitro and benzyloxy derivs. I had anticonvulsive and hypotensive activity.
IT **53012-39-8P 53012-40-1P 53012-44-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and anticonvulsant and antihypertensive activity of)
RN 53012-39-8 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-5-[(2-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 53012-40-1 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-5-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 53012-44-5 CAPLUS
CN 2,4-Imidazolidinedione, 5-[(4-amino-2-chlorophenoxy)methyl]-5-methyl- (9CI) (CA INDEX NAME)



IT **53012-43-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and redn. of)
RN 53012-43-4 CAPLUS
CN 2,4-Imidazolidinedione, 5-[(2-chloro-4-nitrophenoxy)methyl]-5-methyl- (9CI) (CA INDEX NAME)



L81 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1974:79600 CAPLUS
DN 80:79600
TI Model studies of the thymidylate synthetase reaction. Nucleophilic displacement of 5-p-nitrophenoxymethyluracils

AU Pogolotti, Alfonso L., Jr.; Santi, Daniel V.
CS Dep. Biochem. Biophys., Univ. California, San Francisco, Calif., USA
SO Biochemistry (1974), 13(3), 456-66
CODEN: BICHAW
DT Journal
LA English
AB Nucleophilic displacement reactions of 5-p-nitrophenoxymethyluracil and its N-alkylated derivs. were examd. to provide insight into the mechanism by which thymidylate synthetase catalyzes hydride transfer from 5,10-methylenetetrahydrofolate to the Me group of thymidylate. All reactions appear to proceed by formation of highly reactive intermediates having an exocyclic methylene group at the 5-position of the heterocycle rather than direct displacement (SN2) of the leaving group. The driving force for the expulsion of the leaving group and formation of such intermediates may be provided by the N-1 anion, where possible, or by attack of a nucleophile at the 6-position of the heterocycle when the 1-position is alkylated. Direct support for the proposed mechanisms was obtained by evaluation of secondary 2H isotope effects of reactants possessing 2H at the 5-methylene C or the 6-position of the heterocycle. The mechanism involving nucleophilic attack at the 6-position of the heterocycle is analogous to that obsd. in model studies of other reactions catalyzed by this enzyme, and permits a unified mechanism for catalysis, which is supported by all chem. and biochem. data at hand, to be proposed.
Discussion is presented which argues against the existence of a thymidylyl-tetrahydrofolate intermediate in the reaction pathway leading to products.
IT **32078-95-8 32078-98-1 32079-01-9 32079-07-5 52458-45-4**
RL: RCT (Reactant)
(hydrolysis of, thymidylate synthetase reaction mechanism in relation to)
RN 32078-95-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 32078-98-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-methyl-5-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 32079-01-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 3-methyl-5-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 32079-07-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1,3-dimethyl-5-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 52458-45-4 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-aminopropyl)-3-methyl-5-[(4-nitrophenoxy)methyl]-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 52458-44-3
CMF C15 H18 N4 O5



CM 2

CRN 64-19-7
CMF C2 H4 O2



IT **52458-50-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 52458-50-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione,
1-[3-[[(4-methoxyphenyl)diphenylmethyl]amino]p
ropyl]-3-methyl-5-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



L81 ANSWER 34 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1972:419649 CAPLUS
DN 77:19649
TI 1-Aryl-5-(hydroxyalkyl)hydantoins as central nervous system-affecting agents
IN Skorcz, Joseph A.; Suh, John T.
PA Colgate-Palmolive Co.
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 3651079 A 19720321 US 1968-778750 19681125
GI For diagram(s), see printed CA Issue.
AB The arylhydantoins I (R = NO2, NH2; R1 = H, Ac; R2 = H, Me), useful as central nervous system depressants and as antihypertensives, wereprepd. by cyclizing II with KCN-(NH4)2CO3. Thus, 22.5 g of II was refluxed with 9.8 g KCN and 57.7 g (NH4)2CO3 in 50% aq. EtOH to give I (R = NO2, R1 = R2 = H); the related 5-(2-methoxy-4-nitrophenoxy)methyl-5-methylhydantoin is also formed but may be rearranged by further treatment with (NH4)2-CO3-KCN to I. I have i.p. LD50 in mice <500 mg/kg.
IT **29482-31-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 29482-31-3 CAPLUS
CN 2,4-Imidazolidinedione, 5-[(2-methoxy-4-nitrophenoxy)methyl]-5-methyl- (9CI) (CA INDEX NAME)



L81 ANSWER 35 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1971:405838 CAPLUS
DN 75:5838
TI Nucleophilic substitution reactions of 5-acetoxymethyl and 5-p-nitrophenoxymethyluracils
AU Santi, Daniel V.; Pogolotti, A. L., Jr.
CS Dep. Chem., Univ. California, Santa Barbara, Calif., USA
SO J. Heterocycl. Chem. (1971), 8(2), 265-72
CODEN: JHTCAD
DT Journal
LA English
AB The synthesis of 5-(acetoxymethyl)- and 5-(p-nitrophenoxymethyl)uracils and their nucleophilic substitution reactions with MeONa and NaBH4 are reported. These reactions all appear to involve intermediates with carbonium ion character, the formation of which are dependent upon structural features of the heterocycle. Most facile reactions occur when the 1-position of the heterocycle can accommodate a neg. charge to assist in the formation of highly reactive 5-methyleneuracil intermediates. Where ionization is precluded, as with 1-methyl derivs. displacements are retarded but may be assisted by addn. of a nucleophile to the 6-position of the heterocycle. Analogous 1,3-dialkylpyrimidines may react with nucleophiles at the 4-carbonyl group to give anomalous products. Biol. connotations of these reactions are discussed.
IT **32078-95-8P 32078-98-1P 32079-01-9P 32079-07-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 32078-95-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 32078-98-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-methyl-5-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 32079-01-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 3-methyl-5-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 32079-07-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1,3-dimethyl-5-[(4-nitrophenoxy)methyl]- (9CI)
(CA INDEX NAME)



L81 ANSWER 36 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1970:531306 CAPLUS
DN 73:131306
TI Alkylaryloxy alanines, central nervous system stimulants
IN Suh, John T.; Skorcz, Joseph A.
PA Colgate-Palmolive Co.
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3529019	A	19700915	US 1968-723605	19680423

AB The title compds. are prepd. by reacting a substituted ketone with (NH4)2CO3 and KCN in 50 aq. EtOH to form a 5-alkyl-5-(2-alkoxyphenoxy)methylhydantoin which with Ba(OH)2.8H2O forms 2-alkyl-3-(2-alkoxyphenoxy)alanine. Thus, .omicron.-methoxyphenoxyacetone, (NH4)2CO3, and KCN in 50% aq. EtOH refluxed 24 hr and acidified to pH 2 yields 5-methyl-5-(2-methoxyphenoxy)methylhydantion (I), m. 138.5-40.degree. (aq. EtOH). I and Ba(OH)2.8H2O in H2O refluxed 70 hr and acidified forms 2-methyl-3-(2-methoxyphenoxy)alanine, m. 250-2.degree. (aq. Me2CO); Me ester.HCl, m. 120-4.degree., Et ester b0.1 115.degree.. Also prepd. are 10 similar compds.

IT **29482-31-3P 29482-32-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 29482-31-3 CAPLUS
CN 2,4-Imidazolidinedione, 5-[(2-methoxy-4-nitrophenoxy)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 29482-32-4 CAPLUS
CN Hydantoin, 5-[(4-amino-2-methoxyphenoxy)methyl]-5-methyl-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

L81 ANSWER 37 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1970:3708 CAPLUS
DN 72:3708
TI Irreversible enzyme inhibitors. CLXII. Hydrophobic bonding to cytosine nucleoside deaminase with 1-substituted 5-arylcytosines
AU Baker, Bernard Randall; Kelley, James L.
CS Univ. of California, Santa Barbara, Calif., USA
SO J. Med. Chem. (1969), 12(5), 1039-45
CODEN: JMCMAR
DT Journal
LA English
AB 1-Phenoxypropyl-5-phenylcytosine (I) was previously reported to be an inhibitor of cytosine nucleoside deaminase that was complexed one-fourth as well as the substrate, 2'-deoxycytidine. In order to enhance the activity of I, 41 variants were synthesized for e valuation: (a) the 1-phenoxypropyl moiety was as good or better than fiv e other 1-substituents studied; (b) when the 5-phenyl group was substituted with ten different groups, optimum binding occurred with the 3,4-Cl2 substituents; (c) 15 different substituents on the phenoxy moiety gave little change in binding, but showed good bulk tolerance for the large benzamido substituent; (d) five combinations of the substituents on the 2,4-positions of the pyrimidine moiety gave optimum binding with the 2-oxo-4-thione combination. Among the best inhibitors derived from 5-(3,4-dichlorophenyl)cytosine were the 1-(p-chlorophenoxypropyl) and 1-(m-benzamidophenoxypropyl) derivs. which were complexed three-fold better to the enzyme than the substrate.
IT **23572-67-0P 26147-08-0P 26147-09-1P**
26147-10-4P 26159-09-1P 26159-11-5P
26159-12-6P 26159-17-1P 26159-18-2P
26159-19-3P 26250-41-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 23572-67-0 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-(3,4-dichlorophenyl)-1-[3-(2-nitrophenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 26147-08-0 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-(2-nitrophenoxy)propyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 26147-09-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-(3-nitrophenoxy)propyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 26147-10-4 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-(4-nitrophenoxy)propyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 26159-09-1 CAPLUS
CN Cytosine, 5-(3,4-dichlorophenyl)-1-[3-(p-nitrophenoxy)propyl]- (8CI) (CA INDEX NAME)



RN 26159-11-5 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-(3-chloro-4-nitrophenoxy)propyl]-5-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 26159-12-6 CAPLUS
CN Cytosine,
1-[3-(4,5-dichloro-2-nitrophenoxy)propyl]-5-(3,4-dichlorophenyl)-
(8CI) (CA INDEX NAME)



RN 26159-17-1 CAPLUS
CN Cytosine, 1-[3-(o-aminophenoxy)propyl]-5-(3,4-dichlorophenyl)- (8CI) (CA INDEX NAME)



RN 26159-18-2 CAPLUS
CN Cytosine, 1-[3-(m-aminophenoxy)propyl]-5-(3,4-dichlorophenyl)- (8CI) (CA INDEX NAME)



RN 26159-19-3 CAPLUS
CN Cytosine, 1-[3-(p-aminophenoxy)propyl]-5-(3,4-dichlorophenyl)- (8CI) (CA INDEX NAME)



RN 26250-41-9 CAPLUS
CN Cytosine, 5-(3,4-dichlorophenyl)-1-[3-(m-nitrophenoxy)propyl]- (8CI) (CA INDEX NAME)



L81 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1969:68293 CAPLUS
DN 70:68293
TI Irreversible enzyme inhibitors. CXLIII. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 5-[3-(p-aminophenoxy)propyl]-2,4-diamino-6-methylpyrimidine with a terminal sulfonyl fluoride
AU Baker, Bernard Randall; Meyer, Rich B., Jr.
CS Univ. of California, Santa Barbara, Calif., USA
SO J. Med. Chem. (1969), 12(1), 108-11
CODEN: JMCMAR

Searched by John Dantzma 703-308-4488

DT Journal
LA English
AB 2,4-Diamino-5-[3-[p-(m-fluorosulfonylbenzamido)phenoxy]propyl]-6-methylpyrimidine (I) and 3 variants in the benzamido moiety have been synthesized via the intermediate 2-amino-6-methyl-5-[3-(p-nitrophenoxy)propyl]-4-pyrimidinol and 5-[3-(p-aminophenoxy)propyl]-2,4-diamino-6-methylpyrimidine; the key reaction was azide displacement of the Cl of 2-acetamido-4-chloro-6-methyl-5-[3-(p-nitrophenoxy)propyl]pyrimidine followed by redn. of the azidopyrimidine to the 4-aminopyrimidine, since the usual NH3 displacement caused cleavage of the nitrophenoxy side chain. I met all the criteria for in vivo evaluation as an irreversible inhibitor of dihydrofolic reductase, but was inactive in vivo because of poor cell-wall penetration. N-[p-(4,6-Diamino-2,2-dimethyl-1,2-dihydro-s-triazin-1-yl)hydrocinnamoyl]sulfanilyl fluoride showed good penetration of the cell wall and good in vivo activity, but was not a selective irreversible inhibitor of dihydrofolic reductase since it also inactivated the enzyme from mouse liver, spleen, and intestine.
IT **21428-08-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 21428-08-0 CAPLUS
CN Acetamide, N-[4-hydroxy-6-methyl-5-[3-(p-nitrophenoxy)propyl]-2-pyrimidinyl]- (8CI) (CA INDEX NAME)



L81 ANSWER 39 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1967:112442 CAPLUS
DN 66:112442
TI Irreversible enzyme inhibitors. LXIX. Candidate active-site-directed irreversible inhibitors of dihydrofolic reductase. Bromoacyl derivatives of 5-(p-aminophenoxypropyl-2,4,6-triaminopyrimidines
AU Baker, Bernard Randall; Santi, Daniel V.
CS Univ. of California, Santa Barbara, Calif., USA
SO J. Pharm. Sci. (1967), 56(3), 380-4
CODEN: JPMSAE
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB cf. CA 66, 26263a, 62158d. 5-(p-Amino-phenoxypropyl)-2,4,6-triaminopyrimidine (I) was synthesized by alkylation of malononitrile by 3-bromopropyl p-nitrophenyl ether, followed by ring closure with guanidine

and catalytic redn. of the nitro group. Selective haloacylation of the aromatic amino group of I was accomplished by protonation of the triaminopyrimidine moiety of I with acetic acid. Treatment with the anhydrides of bromoacetic acid, p-bromoacetamido-phenylbutyric acid, and N-bromoacetyl-.beta.-alanine gave the pure bromoacyl derivs. These three compds. were good reversible inhibitors of dihydrofolic reductase, but failed to show irreversible inhibition; these failures are attributed to the phenoxypropyl group of the inhibitors being complexed with a hydrophobic region on the enzyme, a region not apt to have groups that could form a covalent bond. 27 references.

IT **15761-66-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 15761-66-7 CAPLUS
CN 4-Pyrimidinol, 2-amino-6-methyl-5-[3-(p-nitrophenoxy)propyl]- (8CI) (CA INDEX NAME)



L81 ANSWER 40 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1967:26263 CAPLUS
DN 66:26263
TI Irreversible enzyme inhibitors. LXVIII. 2-Amino-5-(p-bromoacetamidophenoxypropyl)-6-phenyl-4-pyrimidinol, an active-site-directed irreversible inhibitor of dihydrofolic reductase
AU Baker, Bernard Randall; Shapiro, Howard S.
CS Univ. of California, Santa Barbara, Calif., USA
SO J. Pharm. Sci. (1966), 55(12), 1422-5
CODEN: JPMSAE
DT Journal
LA English
AB cf. preceding abstr.
2-Amino-5-(p-bromoacetamidophenoxypropyl)-6-phenyl-4-pyrimidinol (I), when incubated with dihydrofolic reductase at 37.degree., inactivated the enzyme with a halflife of about 45 min. In contrast, iodoacetamide and p-bromoacetamidophenylbutyric acid at the same conc. no inactivation of the enzyme in the same time. An interesting contrast to I was the 6-Me analog of I which inactivated the enzyme at about one-seventh the rate of I. This result gives unequivocal support for a previous suggestion that 6-methylpyrimidines and 6-phenylpyrimidines do not reversibly complex with dihydrofolic reductase in the same manner, else I and its 6-Me analog should have inactivated the enzyme at the same rate at equal concns. of reversible complex. These expts. are best explained on the basis of active-site-directed irreversible inhibition of dihydrofolic reductase.

Searched by John Dantzma 703-308-4488

IT **14937-56-5P 14937-58-7P 15065-48-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 14937-56-5 CAPLUS
CN 4-Pyrimidinol, 2-amino-5-[3-(p-nitrophenoxy)propyl]-6-phenyl- (8CI) (CA INDEX NAME)



RN 14937-58-7 CAPLUS
CN 4-Pyrimidinol, 2-amino-5-[3-(p-aminophenoxy)propyl]-6-phenyl-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl

RN 15065-48-2 CAPLUS
CN 4-Pyrimidinol, 2-amino-5-[3-(p-aminophenoxy)propyl]-6-methyl-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl

=> d 1-6 all hitstr

L82 ANSWER 1 OF 6 CAOLD COPYRIGHT 2000 ACS
AN CA63:16463e CAOLD
TI protective groups in peptide chemistry
AU Wieland, Theodor
IT 3970-00-1 3970-05-6 3970-06-7 3970-07-8 3970-08-9 3979-44-0
4598-50-9 6344-12-3 **100197-24-8**
IT **100197-24-8**
RN 100197-24-8 CAOLD
CN Salicylaldehyde, 5-chloro-, O,O'-[(3,6-dioxo-2,5-piperazinediyl)dimethylene]dioxime (7CI) (CA INDEX NAME)



L82 ANSWER 2 OF 6 CAOLD COPYRIGHT 2000 ACS
AN CA61:16058c CAOLD
TI mechanism of cycloserine dimerization in the presence of 5-chlorosalicylaldehyde
AU Stammer, Charles H.; McKinney, J. D.
IT 635-93-8 2658-23-3 92440-95-4 93898-35-2 **100197-24-8**
IT **100197-24-8**
RN 100197-24-8 CAOLD
CN Salicylaldehyde, 5-chloro-, O,O'-[(3,6-dioxo-2,5-piperazinediyl)dimethylene]dioxime (7CI) (CA INDEX NAME)



L82 ANSWER 3 OF 6 CAOLD COPYRIGHT 2000 ACS
AN CA61:14672d CAOLD
TI Schiff base of cycloserine
AU Stammer, Charles H.
IT 6344-12-3 91768-75-1 92575-39-8 **100197-24-8**
IT **100197-24-8**
RN 100197-24-8 CAOLD

CN Salicylaldehyde, 5-chloro-, O,O'-[(3,6-dioxo-2,5-piperazinediyl)dimethylene]dioxime (7CI) (CA INDEX NAME)



L82 ANSWER 4 OF 6 CAOLD COPYRIGHT 2000 ACS
AN CA59:7516a CAOLD
TI bis(2-chloroethyl)amines, derivs. of urea and thiourea
AU Berlin, A. Ya.; Levi, I. S.
IT 6720-60-1 88784-24-1 91562-06-0 91646-33-2 91646-34-3 91721-27-6 92021-73-3 93137-10-1 93137-11-2 93868-93-0 93994-77-5 94025-18-0 94025-19-1 94691-27-7 95125-78-3 96434-00-3 97118-40-6 97118-41-7 97491-77-5 97598-06-6 97791-07-6 **98472-85-6**
IT **98472-85-6**
RN 98472-85-6 CAOLD
CN 2-Imidazolidinethione, 1-benzoyl-3-[2-(picryloxy)ethyl]- (7CI) (CA INDEX NAME)



L82 ANSWER 5 OF 6 CAOLD COPYRIGHT 2000 ACS
AN CA54:16655b CAOLD
TI schistosomicidal and toxic effects of some N-p-aminophenoxyalkylamides
AU Collins, Raymond F.; Davis, M.; Edge, N. D.; Hill, J.; Reading, H. W.;

Turnbull, E. R.

IT 100317-01-9 100800-28-0 100840-50-4 100861-96-9 100862-15-5 100958-17-6
101116-78-3 101264-04-4 101275-49-4 101351-09-1 101354-76-1 101438-70-4
101496-69-9 101578-27-2 101586-61-2 101586-70-3 101586-79-2 101587-77-3
101590-04-9 101744-53-0 101785-27-7 101785-64-2 101793-62-8 101939-56-4
102008-47-9 102008-49-1 102008-50-4 102008-63-9 102008-71-9 102016-51-3
102081-66-3 102163-66-6 102164-43-2 102164-84-1 102165-68-4 102167-11-3
102178-85-8 102181-76-0 102181-79-3 102181-80-6 102319-97-1 102375-33-7
102375-34-8 102453-56-5 102457-61-4 102457-85-2 102552-65-8 102556-31-0
102667-13-0 102759-82-0 102809-98-3 102812-68-0 102886-68-0 102955-75-9
103050-73-3 103161-39-3 103168-96-3 103277-13-0 103387-97-9 103388-57-4
103388-58-5 103388-59-6 103503-82-8 103507-77-3 103508-20-9 103509-47-3
103640-92-2 103643-77-2 103643-81-8 103644-25-3 103649-48-5 103758-22-1
104295-14-9 106165-47-8 **106653-05-8** 107627-36-1 107778-44-9
107918-76-3 108367-29-9 108368-14-5 108477-52-7 108984-25-4 109806-61-3
109806-62-4 109808-49-3 111440-64-3 111498-38-5 112971-97-8 113752-63-9
113861-35-1 114889-00-8 115294-19-4 118634-18-7 119299-66-0 119299-67-1
123104-28-9 124105-90-4 132493-51-7

IT **106653-05-8**

RN 106653-05-8 CAOLD

CN Barbituric acid, 1-[5-(p-aminophenoxy)pentyl]- (6CI) (CA INDEX NAME)



L82 ANSWER 6 OF 6 CAOLD COPYRIGHT 2000 ACS

AN CA54:7613f CAOLD

TI chemotheraphy of schistosomiasis - (III) N-(p-aminophenoxyalkyl)amides, -imides, and -sulfonamides

AU Ashley, Julius N.; Collins, R. F.; Davis, M.; Sirett, N. E.

IT 904-10-9 25934-63-8 98395-61-0 99982-26-0 100055-08-1 100254-69-1
100317-01-9 100528-33-4 100531-60-0 100720-45-4 100723-12-4 100840-50-4
100861-96-9 100958-17-6 **100973-99-7** 101116-78-3 101264-04-4
101269-11-8 101270-40-0 101275-49-4 101275-78-9 101275-79-0 101289-48-9
101351-09-1 101354-76-1 101438-70-4 101497-19-2 101575-26-2
101579-81-1 101585-23-3 101586-61-2 101587-15-9 101587-77-3
101715-77-9 101715-90-6 101728-11-4 101732-28-9 101738-01-6 101738-05-0
101738-09-4 101740-15-2 101783-33-9 101785-64-2 101786-01-0 101786-05-4
101793-62-8 101793-97-9 101868-63-7 101878-40-4 101936-15-6 101939-29-1
101939-56-4 102003-31-6 102008-48-0 102008-50-4 102008-63-9 102009-08-5
102016-51-3 102017-05-0 102017-11-8 102081-56-1 102081-66-3 102160-77-0
102163-65-5 102164-43-2 102164-84-1 102164-85-2 102165-68-4 102165-87-7
102167-62-4 102172-69-0 102178-85-8 102182-06-9 102182-10-5 102182-12-7
102240-34-6 102316-95-0 102317-32-8 102318-51-4 102320-11-6 102375-33-7
102443-46-9 102457-85-2 102470-72-4 102556-31-0 102600-32-8 102659-73-4
102660-64-0 102667-13-0 102810-16-2 102812-68-0 102952-06-7 102954-32-5
103046-20-4 103047-05-8 103050-73-3 103100-48-7 103168-96-3 103210-03-3
103211-66-1 103267-38-5 103388-57-4 103388-58-5 103390-68-7 103395-65-9
103403-08-3 103503-82-8 103506-35-0 103506-54-3 103507-12-6 103508-20-9

103640-67-1 103641-74-3 103642-45-1 103644-05-9 103644-87-7 103694-53-7
103758-22-1 103990-75-6 104176-82-1 104295-14-9 105838-73-1 106165-47-3
106273-32-9 106381-78-6 **106653-05-8** 107056-83-7 107419-24-9
107627-36-1 107778-44-9 107918-76-3 108240-51-3 108240-60-4 108246-09-9
108367-29-9 108368-14-5 108368-15-6 108851-37-2 108884-20-4 109037-66-3
109094-52-2 109158-47-6 109399-23-7 109446-11-9 109477-40-9 109557-29-1
109566-95-2 109813-10-7 109814-74-6 109847-65-6 109935-41-3 110530-70-6
110534-68-4 110938-45-9 111142-06-4 111241-28-2 111440-64-3 111978-34-8
112071-51-9 112271-84-8 112624-89-2 112625-46-4 112746-43-7 112971-97-8
113039-22-8 113184-12-6 113325-63-6 113752-63-9 113861-35-1 114034-13-8
114277-18-8 115294-19-4 116604-72-9 116999-72-5 117123-84-9 119417-09-3
119597-35-2 120547-80-0 121622-54-6 122337-11-5 124105-90-4 131240-28-3
131977-44-1 132568-41-3

IT **100973-99-7 101579-81-1 106653-05-8**

RN 100973-99-7 CAOLD

CN Barbituric acid, 1-[5-(p-nitrophenoxy)pentyl]- (6CI) (CA INDEX NAME)



RN 101579-81-1 CAOLD

CN Barbituric acid, 5-acetyl-1-[5-(p-nitrophenoxy)pentyl]- (6CI) (CA INDEX NAME)



RN 106653-05-8 CAOLD

CN Barbituric acid, 1-[5-(p-aminophenoxy)pentyl]- (6CI) (CA INDEX NAME)



```
L45             0 S L35 SSS SAM SUB=L41
L46               SCR 1839 AND 1993 AND 2004 AND 103
L47             1 S L26 AND L46 SSS SAM SUB=L41
L48        529658 S L41 AND NCNC2/ESS
L49             1 S L26 AND L46 SSS SAM SUB=L48
L50        298725 S NCNC2/ES AND O/ELS AND NRS>1
L51             1 S L26 SSS SAM SUB=L50
L52        285783 S NC2NC2/ESS AND O/ELS AND NRS>1
L53        284158 S L52 NOT SEQ/FA
L54             0 S L25 SSS SAM SUB=L53
L55        598235 S NCNC2/ESS AND O/ELS AND NRS>1
L56        529658 S L55 NOT SEQ/FA
L57             1 S L26 AND L46 SSS SAM SUB=L56
L58        585983 S NCNC3/ESS AND O/ELS AND NRS>1
L59        576308 S L58 NOT SEQ/FA
L60             0 S L35 SSS SAM SUB=L59
L61             0 S L35 AND L46 SSS SAM SUB=L59
L62               SCR 1839 AND 1993 AND 2004 AND 150
L63             2 S L26 AND L62 SSS SAM SUB=L56
L64               SCR 1950
L65             1 S L35 OR L26 AND L62 SSS SAM SUB=L41
L66               SCR 1950
L67             1 S L26 AND L62 AND L66 SSS SAM SUB=L56
L68             3 S L26 AND L62 NOT L66 SSS SAM SUB=L56
L69             0 S L35 AND L46 SSS SAM SUB=L59
L70             0 S L35 AND L46 AND L66 SSS SAM SUB=L59
L71             0 S L35 AND L46 NOT L66 SSS SAM SUB=L59
L72           110 S L35 AND L46 NOT L66 SSS FUL SUB=L59
L73            21 S L35 AND L46 AND L66 SSS FUL SUB=L59
L74            82 S L26 AND L62 AND L66 SSS FUL SUB=L56
L75           220 S L26 AND L62 NOT L66 SSS FUL SUB=L56
L76           481 S L25 SSS FUL SUB=L53
                  SAV QAZ535A/A L72
                  SAV QAZ535B/A L73
                  SAV QAZ535C/A L74
                  SAV QAZ535D/A L75
                  SAV QAZ535E/A L76
L77           914 S L72-L76
L78               STR L25
L79             3 S L78 SSS SAM SUB=L77
L80           135 S L78 SSS FUL SUB=L77

     FILE 'CAPLUS' ENTERED AT 14:53:38 ON 05 JUL 2000
L81            40 S L80

     FILE 'CAOLD' ENTERED AT 14:58:00 ON 05 JUL 2000
L82             6 S L80

     FILE 'REGISTRY' ENTERED AT 14:58:23 ON 05 JUL 2000
                SAV L80 QAZI535F/A
```

=> d his

(FILE 'HOME' ENTERED AT 13:31:57 ON 05 JUL 2000)

FILE 'HCAPLUS' ENTERED AT 13:32:02 ON 05 JUL 2000

```
L1          23 S LOHRAY V?/AU
L2          84 S LOHRAY B?/AU
L3           7 S PARASELLI R?/AU
L4           4 S GURRAM R?/AU
L5          40 S RAMANUJAM R?/AU
L6         160 S CHAKRABARTI R?/AU
L7           6 S PAKALA S?/AU
L8           2 S L1 AND L2 AND L3 AND L4 AND L5 AND L6 AND L7
               SELECT RN L8 1-2
```

FILE 'REGISTRY' ENTERED AT 13:33:17 ON 05 JUL 2000

```
L9         116 S E1-116
```

FILE 'HCAPLUS' ENTERED AT 13:33:55 ON 05 JUL 2000

```
L10          2 S L8 AND L9
```

FILE 'REGISTRY' ENTERED AT 13:36:42 ON 05 JUL 2000

```
L11            STR
L12          6 S L11
L13            STR L11
L14          6 S L13
L15            STR L13
L16          0 S L15 AND L13
L17            SCR 1839 AND 2004 AND 1993
L18          0 S L15 AND L13 AND L17
L19          6 S L13 AND L17
L20            SCR 150 AND 1839 AND 2004 AND 1993
L21         10 S L13 AND L20
L22            STR L13
L23          3 S L22 AND L20
L24          0 S L22 AND L15 AND L20
L25            STR L22
L26            STR L25
L27          0 S L25 OR L26 AND L20
L28            SCR 1951
L29          2 S L25 OR L26 AND L20 AND L28
L30          1 S L25 OR L26 AND L20 NOT L28
L31            SCR 1950
L32          1 S L25 OR L26 AND L20 NOT L31
L33          0 S L25 OR L26 AND L20 AND L31
L34            SCR 146 OR 150
L35            STR L25
L36          0 S (L25 OR L26 OR L35) AND L34 AND L17
L37    1269154 S (NC2NC2 OR NCNC3 OR NCNC2)/ESS AND O/ELS AND NRS>1
L38          1 S (L25 OR L26 OR L35) AND L34 AND L17 SSS SAM SUB=L37
L39            STR
L40          0 S L39 AND (L25 OR L26 OR L35) AND L34 AND L17 SSS SAM SUB=L37
L41    1197292 S L37 NOT SEQ/FA
L42          0 S L39 AND (L25 OR L26 OR L35) AND L34 AND L17 SSS SAM SUB=L41
L43          0 S L25 SSS SAM SUB=L41
L44          2 S L26 SSS SAM SUB=L41
```

=> d que 180

L25 STR



REP G2=(0-7) CH2
VAR G3=CHO/NO2/NH2/11/14/19/29/42
VAR G4=H/28
VPA 6-37/38 U
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 28
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE
L26 STR



REP G2=(0-7) CH2
VAR G3=CHO/NO2/NH2/11/14/19/29/42
VAR G4=H/28
VPA 6-37/38/36 U
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 28
DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE
L35 STR



REP G2=(0-7) CH2
VAR G3=CHO/NO2/NH2/11/14/19/29/42
VAR G4=H/28
VPA 6-39/38/37/36 U
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 28
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE

L46		SCR 1839 AND 1993 AND 2004 AND 103
L52	285783	SEA FILE=REGISTRY ABB=ON PLU=ON NC2NC2/ESS AND O/ELS AND NRS>1
L53	284158	SEA FILE=REGISTRY ABB=ON PLU=ON L52 NOT SEQ/FA
L55	598235	SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2/ESS AND O/ELS AND NRS>1
L56	529658	SEA FILE=REGISTRY ABB=ON PLU=ON L55 NOT SEQ/FA
L58	585983	SEA FILE=REGISTRY ABB=ON PLU=ON NCNC3/ESS AND O/ELS AND NRS>1
L59	576308	SEA FILE=REGISTRY ABB=ON PLU=ON L58 NOT SEQ/FA
L62		SCR 1839 AND 1993 AND 2004 AND 150
L66		SCR 1950
L72	110	SEA FILE=REGISTRY SUB=L59 SSS FUL L35 AND L46 NOT L66
L73	21	SEA FILE=REGISTRY SUB=L59 SSS FUL L35 AND L46 AND L66
L74	82	SEA FILE=REGISTRY SUB=L56 SSS FUL L26 AND L62 AND L66
L75	220	SEA FILE=REGISTRY SUB=L56 SSS FUL L26 AND L62 NOT L66
L76	481	SEA FILE=REGISTRY SUB=L53 SSS FUL L25
L77	914	SEA FILE=REGISTRY ABB=ON PLU=ON (L72 OR L73 OR L74 OR L75 OR

L78 L76)
STR



REP G2=(0-7) CH2
VAR G3=CHO/NO2/NH2/11/14/19/29/42
VAR G4=H/28
VAR G5=O/S
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 28
DEFAULT MLEVEL IS ATOM
GGCAT IS HIQ AT 45
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M2 N AT 45

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE
L80 135 SEA FILE=REGISTRY SUB=L77 SSS FUL L78

=> d bib abs hitstr 16-40

L81 ANSWER 16 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1993:649760 CAPLUS
DN 119:249760
TI Porphyrins coupled with nucleoside bases. Synthesis and characterization of ether-linked adenine-thymine and guanine-cytosine derivatives
AU Hisatome, Masao; Ikeda, Koichi; Kishibata, Shusuke; Yamakawa, Koji
CS Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan
SO Chem. Lett. (1993), (8), 1357-60
CODEN: CMLTAG; ISSN: 0366-7022
DT Journal
LA English
GI



I

AB Porphyrins I (B = adenine, guanine, thymine, cytosine, R = H; B = adenine, R = thyminylbutoxy; B = guanine, R = cytosinylbutoxy) have been synthesized. Spectroscopic study has revealed that in I [R = O(CH2)4B1] the two nucleic acid bases form inter- and intramol. base pairs in the anti and syn atropisomers, resp., and that the guanine-cytosine pair is closer to the porphyrin ring than the adenine-thymine pair.

IT **151056-15-4P 151056-16-5P 151056-18-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(intermediate in prepn. of nucleic acid base-contg. porphyrins)

RN 151056-15-4 CAPLUS
CN Benzaldehyde, 2-[4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)butoxy]- (9CI) (CA INDEX NAME)



RN 151056-16-5 CAPLUS
CN Benzaldehyde, 2-[4-(4-amino-2-oxo-1(2H)-pyrimidinyl)butoxy]- (9CI) (CA INDEX NAME)



RN 151056-18-7 CAPLUS
CN Benzaldehyde, 2-[4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)butoxy]-(9CI)
(CA INDEX NAME)



L81 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1993:560277 CAPLUS
DN 119:160277
TI Preparation of imidazolidinetrione derivatives as intermediates for ulcer inhibitors
IN Matsukubo, Hiroshi; Myashita, Mitsutomo; Koike, Tomozo; Harano, Naoki; Maeda, Toshio
PA Kyorin Seiyaku Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05086036	A2	19930406	JP 1991-273246	19910925

OS CASREACT 119:160277; MARPAT 119:160277
GI



I



II

AB The title compds. [I; R1 = alkyl; A = CH2CH2, propylene, butylene, butenylene; X = halo, m-formylphenoxy], intermediates for the antiulcer

drug II, are prepd. via, e.g., reaction of urea derivs. X-A-NH-CO-NH-R1 with (COCl)2. E.g., (COCl)2 was added dropwise to Cl(CH2)3-NH-CO-NH-Et in CH2Cl2 at .ltoreq.10.degree. and the resulting mixt. was stirred at room temp. for 21 h to give the title compd. 1-(3-chloropropyl)-3-ethylimidazolidinetrione. This when reacted with 3-hydroxybenzaldehyde in DMF contg. KHCO3 gave antiulcer II.

IT **149911-68-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for ulcer inhibitor)

RN 149911-68-2 CAPLUS

CN Benzaldehyde, 3-[3-(3-ethyl-2,4,5-trioxo-1-imidazolidinyl)propoxy]- (9CI) (CA INDEX NAME)



L81 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2000 ACS

AN 1990:98478 CAPLUS

DN 112:98478

TI Sodium 2-mercaptoethanesulfonate in reversible adduct formation and water solubilization

AU Rise, Frode; Undheim, Kjell

CS Inst. Chem., Univ. Uppsala, Uppsala, S-751 21, Swed.

SO Acta Chem. Scand. (1989), 43(5), 489-92
CODEN: ACHSE7

DT Journal

LA English

GI



II



III

AB Sodium 2-mercaptoethanesulfonate (I, coenzyme M) forms 1:1 covalent adducts with high .pi.-electron deficient heterocycles. The addn. is at the thiol function, and the adducts become water sol. as sulfonates. 1H NMR spectroscopy was used to obtain information about electronic and steric effects on the equil. between 2-pyrimidinones and their 1:1 adducts with I. The adducts, e.g., II and III, are potential prodrugs for biol. interesting 2-pyrimidinones.

IT **100944-95-4**
RL: RCT (Reactant)
(addn. reaction of, with sodium mercaptoethanesulfonate, reversibility and regiochem. of)

RN 100944-95-4 CAPLUS

CN Benzaldehyde, 4-[(5-chloro-2-oxo-1(2H)-pyrimidinyl)methoxy]- (9CI) (CA INDEX NAME)



IT **125256-32-8P 125256-42-0P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and NMR of)

RN 125256-32-8 CAPLUS

CN Ethanesulfonic acid, 2-[[5-chloro-1-[(4-formylphenoxy)methyl]-1,2,3,4-tetrahydro-2-oxo-4-pyrimidinyl]thio]-, monosodium salt (9CI) (CA INDEX NAME)



RN 125256-42-0 CAPLUS

CN Ethanesulfonic acid, 2-[[5-chloro-3-[(4-formylphenoxy)methyl]-1,2,3,4-tetrahydro-2-oxo-4-pyrimidinyl]thio]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

L81 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1990:77145 CAPLUS
DN 112:77145
TI A cage compound derived from cyclotriveratrylene and diphenylglycoluril subunits
AU Smeets, J. W. H.; Coolen, H. K. A. C.; Zwikker, J. W.; Nolte, R. J. M.
CS Dep. Org. Chem., Univ. Utrecht, Utrecht, 3584 CH, Neth.
SO Recl. Trav. Chim. Pays-Bas (1989), 108(6), 215-18
CODEN: RTCPA3; ISSN: 0165-0513
DT Journal
LA English
OS CASREACT 112:77145
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compd. I was prepd. as a mixt. of stereoisomers in 4 steps from vanillin. Monoetherification of vanillin with Br(CH2)6Br and exhaustive alkylation of diphenylglycoluril with the adduct thus prepd. gave diphenyltetrakis[(aryloxy)hexyl]glycoluril II. NaBH4 redn. of II, followed by high-diln. cyclotrimerization of the reduced product in HCO2H contg. Me2NCHO gave 31% I. I has a well defined cavity and a free functionalized arm.

IT **125232-26-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and redn. of, with sodium borohydride)

RN 125232-26-0 CAPLUS

CN Benzaldehyde,
4,4',4'',4'''-[(dihydro-2,5-dioxo-3a,6a-diphenylimidazo[4,5-d]imidazole-1,3,4,6(2H,5H)-tetrayl)tetrakis(6,1-hexanediyloxy)]tetrakis[3-methoxy- (9CI) (CA INDEX NAME)



L81 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1989:189240 CAPLUS
DN 110:189240
TI Synthesis and antibacterial activity of some new 2-aryloxymethyl-3-substituted-quinazolin-4(3H)-ones
AU Khan, A.; Saksena, R. K.
CS D. A. V. Coll., Kanpur Univ., Kanpur, India
SO Pharmazie (1988), 43(12), 864-5
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA English
AB Halogenated quinazolinones were synthesized, and 2-aryloxymethyl-3-arylquinazolin-4(3H)-ones and 2-aryloxymethyl-3-(2-substituted ethyl)quinazolin-4(3H)-ones were screened for antibacterial activity. Most compds. in each group showed some activity.
IT **120244-20-4P 120244-25-9P 120244-29-3P**
120244-30-6P 120268-13-5P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antibacterial activity of)
RN 120244-20-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-nitrophenoxy)methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 120244-25-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methylphenyl)-2-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 120244-29-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chloroethyl)-2-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 120244-30-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-fluoroethyl)-2-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 120268-13-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-hydroxyethyl)-2-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



IT **120244-31-7**
RL: RCT (Reactant)
(reaction of, with aminoethanol)
RN 120244-31-7 CAPLUS
CN 4(1H)-Quinazolinone, 2-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



L81 ANSWER 21 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1988:437790 CAPLUS
DN 109:37790
TI Sulfonic and phosphonic acids formed by bisulfite and phosphite adduct formation with pyrimidinones
AU Benneche, Tore; Strande, Per; Undheim, Kjell
CS Dep. Chem., Univ. Oslo, Oslo, N-0315, Norway
SO Acta Chem. Scand., Ser. B (1987), B41(6), 448-54
CODEN: ACBOCV; ISSN: 0302-4369
DT Journal
LA English
OS CASREACT 109:37790
GI



AB Alkylation of pyrimidinone I (R = H) with ClCHR1R2 [R1 = H, Me, Ph; R2 = OPh, substituted PhO, N(CO2Et)CH2Ph, SC6H4Cl-4, SCH2Ph, 2-naphthyloxy] gave N- and O-alkylated products I (R = CHR1R2) and II. Sulfurization of I (R = CHR1R2) gave pyrimidines III (R3 = SO3Na) as well as 3,6-bisulfites. Phosphorylation of I (R = CH2Ph, CH2OCH2C6H4Cl-4) gave regiospecifically III (R1 = H; R2 = Ph, OCH2C6H4Cl-4; R3 = PO3H2) via hydrolysis.
IT **100944-58-9P 100944-59-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and desulfurization of)
RN 100944-58-9 CAPLUS
CN 4-Pyrimidinesulfonic acid, 5-chloro-1-[(4-formylphenoxy)methyl]-1,2,3,4-tetrahydro-2-oxo-, monosodium salt (9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)



=> d bib abs hitstr 15

L81 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1994:106638 CAPLUS
DN 120:106638
TI The synthesis of a potential anti-cancer agent containing the caffeine and
1,2,3-benzotriazine moieties
AU Parrick, John; Mehta, Lina K.; Hodgkiss, Richard J.
CS Dep. Chem., Brunel Univ., Uxbridge/Middlesex, UB8 3PH, UK
SO J. Heterocycl. Chem. (1993), 30(2), 323-7
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 120:106638
GI



I



II

AB The potential anti-cancer agent I has been synthesized from 4-(4-chlorobutoxy)-2-nitroaniline via benzotriazine N-oxide II. Theophylline has been reacted with II to give the N-oxide, which was oxidized to I. I has been found to be ineffective as a radiosensitizer.

IT **152538-23-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. of)
RN 152538-23-3 CAPLUS
CN 1H-Purine-2,6-dione, 7-[4-[(3-amino-4-oxido-1,2,4-benzotriazin-7-yl)oxy]butyl]-3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



IT **152538-24-4P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as anticancer agent)
RN 152538-24-4 CAPLUS
CN 1H-Purine-2,6-dione, 7-[4-[(3-amino-1,4-dioxido-1,2,4-benzotriazin-7-yl)oxy]butyl]-3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***



● Na

RN 100944-59-0 CAPLUS
CN 4-Pyrimidinesulfonic acid, 5-chloro-3-[(4-formylphenoxy)methyl]-1,2,3,4-tetrahydro-2-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

IT **100944-95-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sulfurization of, with bisulfites)
RN 100944-95-4 CAPLUS
CN Benzaldehyde, 4-[(5-chloro-2-oxo-1(2H)-pyrimidinyl)methoxy]- (9CI) (CA INDEX NAME)



L81 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1988:123961 CAPLUS
DN 108:123961
TI DNA-nitrosourea interactions. High-performance liquid chromatography of cross-linked dinucleosides and substituted deoxynucleosides
AU Maggio, A. F.; Pompon, A.; Lucas, M.; Barascut, J. L.; Imbach, J. L.
CS Lab. Chim. Bio-Organ., Univ. Sci. Tech., Montpellier, 34060, Fr.
SO J. Chromatogr. (1988), 436(1), 23-30
CODEN: JOCRAM; ISSN: 0021-9673
DT Journal

LA English
AB A reconstituted mixt. of 5 cross-linked dinucleosides possibly involved in
DNA-nitrosourea interactions, and of their degrdn. products (nucleobases, deoxynucleosides and mono- or disubstituted deoxynucleosides), was analyzed by reversed-phase HPLC using C18 columns and a diode-array detector. The chromatog. conditions for sepg. the 21 investigated compds.
were optimized, and the compds. were identified by both their retention times and their UV spectra. A structure-retention time relationship was obsd. under suitable conditions and is discussed. Its validity was confirmed by the prediction of the retention time of a cross-linked dinucleoside synthesized for this purpose.
IT **111447-28-0 111447-29-1**
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, by HPLC, in reconstructed mixt. of cross-linked dinucleosides and their degrdn. products)
RN 111447-28-0 CAPLUS
CN Guanosine, 2'-deoxy-6-O-[2-[3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111447-29-1 CAPLUS
CN Guanosine, 2'-deoxy-6-O-[2-[3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6-dihydro-6-imino-2-oxo-1(2H)-pyrimidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1987:637188 CAPLUS
DN 107:237188
TI Regioselective synthesis of linked dinucleosides: reaction mechanism of nitrosoureas
AU Maggio, A. F.; Lucas, M.; Barascut, J. L.; Pompon, A.; Imbach, J. L.
CS Lab. Chim. Bio-Org., Univ. Sci. Tech. Languedoc, Montpellier, 34060, Fr.
SO Nouv. J. Chim. (1986), 10(11), 643-50
CODEN: NJCHD4; ISSN: 0398-9836
DT Journal
LA French
OS CASREACT 107:237188
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Linked dinucleosides were regioselectively prepn. by linking deoxyguanosine (I), deoxycytidine, (II), and deoxyuridine synthons. E.g., the condensation of synthon III of I with synthon IV of II and deprotection gave the guanosylcytidylethane V.
IT **111447-28-0P 111447-29-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 111447-28-0 CAPLUS
CN Guanosine, 2'-deoxy-6-O-[2-[3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111447-29-1 CAPLUS
CN Guanosine, 2'-deoxy-6-O-[2-[3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6-dihydro-6-imino-2-oxo-1(2H)-pyrimidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 24 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1986:129922 CAPLUS
DN 104:129922
TI Pyrimidinone derivatives
IN Undheim, Kjell; Benneche, Tore
PA Nyegaard og Co. A/S, Norway
SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 160573	A2	19851106	EP 1985-303102	19850501
	EP 160573	A3	19861120		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	NO 8501714	A	19851104	NO 1985-1714	19850430
	DK 8501970	A	19851103	DK 1985-1970	19850502
	JP 61010562	A2	19860118	JP 1985-93948	19850502
PRAI	GB 1984-11291	19840502			

GI



I



II



III

AB Bisulfite addn. products of pyrimidinones I [R1 = CF3, halo; R2 = H, alkyl, alkanoyl, Ph; R3 = (un)substituted arom., heteroarom.; R4, R5 = H, alkyl; X = O, S, R6N; R6 = CHO, alkanoyl, alkoxycarbonyl; n = 0, 1], useful as neoplasm inhibitors (no data), were prepd. Thus, 4-HOC6H4CHO was alkylated with MeSCH2Cl to give 4-MeSCH2OC6H4CHO which was treated with SO2Cl2 to give 4-ClCH2OC6H4CHO. The latter was treated with 5-chloro-2(1H)-pyrimidinone-HCl to give I (R1 = Cl, R2 = H, R3 = 4-OCHC6H4, X = O, n = 0) which was stirred at room temp. in aq. NaHSO3 to give isomeric bisulfite addn. products II and III.

IT **100944-94-3P 100944-95-4P 100945-07-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and addn. reaction of, with sodium bisulfite)

RN 100944-94-3 CAPLUS

CN 2(1H)-Pyrimidinone, 5-chloro-1-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 100944-95-4 CAPLUS
CN Benzaldehyde, 4-[(5-chloro-2-oxo-1(2H)-pyrimidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 100945-07-1 CAPLUS
CN Benzaldehyde, 4-[[2-oxo-5-(trifluoromethyl)-1(2H)-pyrimidinyl]methoxy]- (9CI) (CA INDEX NAME)



IT **100944-58-9P 100944-59-0P 100944-64-7P**
100944-65-8P 100944-67-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as neoplasm inhibitor)
RN 100944-58-9 CAPLUS
CN 4-Pyrimidinesulfonic acid, 5-chloro-1-[(4-formylphenoxy)methyl]-1,2,3,4-tetrahydro-2-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 100944-59-0 CAPLUS
CN 4-Pyrimidinesulfonic acid, 5-chloro-3-[(4-formylphenoxy)methyl]-1,2,3,4-tetrahydro-2-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 100944-64-7 CAPLUS
CN 4-Pyrimidinesulfonic acid,
1-[(4-formylphenoxy)methyl]-1,2,3,4-tetrahydro-
2-oxo-5-(trifluoromethyl)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 100944-65-8 CAPLUS
CN 4-Pyrimidinesulfonic acid,
3-[(4-formylphenoxy)methyl]-1,2,3,4-tetrahydro-
2-oxo-5-(trifluoromethyl)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 100944-67-0 CAPLUS
CN 4-Pyrimidinesulfonic acid, 5-chloro-1,2,3,4-tetrahydro-1-[(4-
nitrophenoxy)methyl]-2-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

L81 ANSWER 25 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1983:179330 CAPLUS
DN 98:179330
TI Reaction of quinoxaline derivatives with nucleophilic reagents
AU Badr, Mahmoud Zarif Amin; El-Naggar, Galal Mohamed; El-Sherief, Hassan Ahmad Hassan; Abdel-Rahman, Abdou El-Sayed; Aly, Moustafa Fouzy
CS Fac. Sci., Assiut Univ., Assiut, Egypt
SO Bull. Chem. Soc. Jpn. (1983), 56(1), 326-30
CODEN: BCSJA8; ISSN: 0009-2673
DT Journal
LA English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Treatment of 2-chloro-3-methylquinoxaline with arom. amines in basic medium gave aminoquinoxalines I (R = H, Me, Cl) and with HSCH2CO2H gave thioether II. Condensation of 3-methyl-2(1H)-quinoxalinone with arom. aldehydes gave styrylquinoxalines III (R1 = H, Me, Me2N, Cl, HO, NO2) which added Br2 in HOAc to give dibromo derivs. which reacted with morpholine, NaOMe, and piperidine to give phenethylquinoxalines IV (R1 = 4-MeO, R2 = morpholino; R1 = 4-NO2, R2 = MeO) and V. 3-(Bromomethyl)-2(1H)-quinoxalinone underwent nucleophilic substitution with arom. amines, Na saccharine, and K phthalimide, and 3-methyl-2(1H)-quinoxalinethione underwent S-alkylation by Me2SO4 and ClCH2CO2H and BrCH2CH2CO2H.

IT **85516-32-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 85516-32-1 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[(4-nitrophenoxy)methyl]- (9CI) (CA INDEX NAME)



L81 ANSWER 26 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1983:72028 CAPLUS
DN 98:72028
TI Some new 2-aryloxymethyl-3-.alpha.-substituted carboxymethyl-6,8-substituted 4-quinazolones as possible anticonvulsants
AU Husain, M. I.; Singh, Eira
CS Chem. Dep., Lucknow Univ., Lucknow, India
SO Pharmazie (1982), 37(6), 408-10
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA English
GI



I



II

AB The title compds. I (R = 3,4-Me2, p-O2N, H, p-Me, o-Cl; R2 =H, Br; R3 = H, Br, iodo, R4 = H, PhCH2, Me, imidazolylmethyl Me2CH, H2CC(:NH)NH(CH2)3, MeCEt, Me2CHCH2, H2NCOCH2CH2) were prepd. by treating the anthranils II with H2NCHR4CO2H. Most I gave 20-60% anticonvulsant protection against pentylenetetrazole induced seizures. The monoamine oxidase activity of I was also reported.

IT **83793-67-3P 83793-68-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 83793-67-3 CAPLUS
CN 3(4H)-Quinazolineacetic acid, 8-iodo-2-[(4-nitrophenoxy)methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 83793-68-4 CAPLUS
CN 3(4H)-Quinazolineacetic acid, .alpha.-(1-methylethyl)-2-[(4-nitrophenoxy)methyl]-4-oxo-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **83793-69-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., anticonvulsant, and monoamine oxidase activity of)
RN 83793-69-5 CAPLUS
CN 3(4H)-Quinazolineacetic acid, .alpha.-(1H-imidazol-1-ylmethyl)-2-[(4-nitrophenoxy)methyl]-4-oxo-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 27 OF 40 CAPLUS COPYRIGHT 2000 ACS
AN 1980:620689 CAPLUS
DN 93:220689
TI Synthesis of 2-phenoxymethyl-3-(2'-pyridyl/thiazolyl)-4-quinazolones as possible antifertility drugs
AU Shukla, J. S.; Ahmad, I.

CS Dep. Chem., Univ. Lucknow, Lucknow, India
SO Indian J. Chem., Sect. B (1979), 17B(6), 651-2
CODEN: IJSBDB; ISSN: 0376-4699
DT Journal
LA English
GI



I

AB 2-Phenoxymethyl-3-(2-pyridyl/thiazolyl)-4-quinazolones I (R = H, Me, NO2, OMe; R1 = H, Br, iodo; R2 = H, Br; R3 = 2-pyridyl, 2-thiazolyl) were prepd. by cyclization of the substituted anthranilic acids with phenoxyacetyl chlorides followed by condensation with R3NH2.

IT **73342-54-8P 73342-55-9P 75543-04-3P**
75543-05-4P 75543-06-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 73342-54-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-nitrophenoxy)methyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 73342-55-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-nitrophenoxy)methyl]-3-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 75543-04-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-2-[(4-nitrophenoxy)methyl]-3-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 75543-05-4 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[(4-nitrophenoxy)methyl]-3-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 75543-06-5 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[(4-nitrophenoxy)methyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)